Načítá se...

Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait

Hybridoma-derived idiotype vaccines have been used for the experimental treatment of human lymphoma over the last twenty years, providing evidence of biological efficacy, clinical efficacy and clinical benefit. However, the product that has come closer to regulatory approval is unlikely to clear tha...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Bendandi, Maurizio
Médium: Artigo
Jazyk:Inglês
Vydáno: Molecular Diversity Preservation International 2010
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4033974/
https://ncbi.nlm.nih.gov/pubmed/27713273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph3030667
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!